Kaminski HJ, Sikorski P, Coronel SI, Kusner LL (2024) Myasthenia Gravis: the future is here. J Clin Invest 134(12):e179742. https://doi.org/10.1172/JCI179742

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cavalcante P, Mantegazza R, Antozzi C (2024) Targeting autoimmune mechanisms by precision medicine in myasthenia Gravis. Front Immunol 15:1404191. https://doi.org/10.3389/fimmu.2024.1404191

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alfaidi N, Karmastaji S, Matic A, Bril V (2024) FcRn inhibitor therapies in neurologic diseases. CNS Drugs 38(6):425–441. https://doi.org/10.1007/s40263-024-01090-3

Article  PubMed  Google Scholar 

Heo Y-A (2022) Efgartigimod: first approval. Drugs 82:341–348. https://doi.org/10.1007/s40265-022-01678-3

Hoy SM, Rozanolixizumab (2023) First Approval Drugs 83(14):1341–1347. https://doi.org/10.1007/s40265-023-01933-1

Article  CAS  PubMed  Google Scholar 

Spagni G, Gastaldi M, Businaro P et al (2023) Comparison of fixed and live cell-based assay for the detection of achr and musk antibodies in myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm 10:e200038. https://doi.org/10.1212/NXI.0000000000200038

Article  PubMed  Google Scholar 

Sorrenti B, Laurini C, Bosco L et al (2024) Overcoming therapeutic challenges: successful management of a supposedly triple seronegative, refractory generalized myasthenia Gravis patient with Efgartigimod. Eur J Neurol 31(7):e16306. https://doi.org/10.1111/ene.16306

Article  PubMed  PubMed Central  Google Scholar 

Frangiamore R, Rinaldi E, Vanoli F et al (2024) Efgartigimod in generalized myasthenia Gravis: A real-life experience at a National reference center. Eur J Neurol 31(4):e16189. https://doi.org/10.1111/ene.16189

Article  PubMed  PubMed Central  Google Scholar 

Jaretzki A 3rd 1, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 12;55;16–23

Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of MG-ADL in myasthenia Gravis clinical research and care. Muscle Nerve 65:630–639

Article  PubMed  PubMed Central  Google Scholar 

Burns TM, Conaway M, Sanders DB (2010) The MG composite. A valid and reliable measure for myasthenia Gravis. Neurology 74:1434–1440

Article  PubMed  PubMed Central  Google Scholar 

Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB (2005) Quantitative myasthenia Gravis: assessment of responsiveness and longitudinal validity. Neurology 64:196

Article  Google Scholar 

Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia Gravis activities of daily living profile. Neurology 52:1487–1489

Article  CAS  PubMed  Google Scholar 

Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW (1998) Reliability testing of the quantitative myasthenia Gravis score. Ann N Y Acad Sci 841:769–772

Article  CAS  PubMed  Google Scholar 

Burns TM, Sadjadi R, Utsugisawa K et al (2016) International clinimetric evaluation of the MG-Qol15, resulting in slight revision and subsequent validation of the MG-Qol15r. Muscle Nerve 54:1015–1022

Article  PubMed  Google Scholar 

Zhang B, Tzartos JS, Belimezi M et al (2012) Autoantibodies to Lipoprotein-Related protein 4 in patients with double-seronegative myasthenia Gravis. Arch Neurol 69:445–451

Article  PubMed  Google Scholar 

Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA (2022) Utilization of MG-ADL in myasthenia Gravis clinical research and care. Muscle Nerve 65(6):630–639. https://doi.org/10.1002/mus.2747

Article  PubMed  PubMed Central  Google Scholar 

Vissing J, Jacob S, Fujita KP, O’Brien F, Howard JF, REGAIN study group (2020) Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia Gravis treated with Eculizumab. J Neurol 267(7):1991–2001. https://doi.org/10.1007/s00415-020-09770-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iorio R (2024) Myastenia Gravis: the changing treatment landscape in the era of molecular therapy. Nat Rev Neurol 20(2):84–98. https://doi.org/10.1038/s41582-023-00916-w

Article  CAS  PubMed  Google Scholar 

Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of Efgartigimod in patients with generalized myasthenia Gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526–536

Article  CAS  PubMed  Google Scholar 

Howard JF Jr, Bril V, Vu T et al (2024) Long-term safety, tolerability, and efficacy of Efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia Gravis. Front Neurol 14:1284444. https://doi.org/10.3389/fneur.2023.1284444

Article  PubMed  PubMed Central  Google Scholar 

Morell A, Terry WD, Waldamann TA (1970) Metabolic properties of IgG subclasses in man. J Clin Invest 49:673–680

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Mantegazza R, Antozzi C (2024) Efgartigimod improves triple-negative myasthenia Gravis. Neurol Sci 45:1307–1309. https://doi.org/10.1007/s10072-023-07122-y

Article  PubMed  Google Scholar 

Mehrabyan A, Traub RE (2024) Retrospective review of patients with myasthenia Gravis switched from plasma exchange therapy to Efgartigimod treatment. Muscle Nerve 69(4):467–471. https://doi.org/10.1002/mus.28042Epub 2024 Jan 29

Article  CAS  PubMed  Google Scholar 

Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K (2024) Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscul Disord 39:37–41. https://doi.org/10.1016/j.nmd.2024.04.005. Epub 2024 Apr 23. PMID: 38772072

Suzuki S, Uzawa A, Nagane Y et al (2024) Therapeutic responses to Efgartigimod for generalized myasthenia Gravis in Japan. Neurol Clin Pract 14(3):e200276. https://doi.org/10.1212/CPJ.0000000000200276

Article  PubMed  PubMed Central  Google Scholar 

Luo S, Jiang Q, Zeng W et al (2024) Chinese myasthenia Gravis collaborating group (CMGCG). Epub Efgartigimod for generalized myasthenia Gravis: A multicenter real-world cohort study in China. Ann Clin Transl Neurol 11(8):2212–2221. https://doi.org/10.1002/acn3.52142Epub 2024 Jul 7. PMID: 389731092024 Mar 25. PMID: 38544885

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu G, Ma Y, Zhou H et al (2024) Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod. Front Immunol 15:1401972. https://doi.org/10.3389/fimmu.2024.1401972. eCollection 2024. PMID: 38911858

Song J, Wang H, Huan X et al (2024) Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol 15:1418503. https://doi.org/10.3389/fimmu.2024.1418503. eCollection 2024. PMID: 39136012

Pane C, Di Stefano V, Cuomo N et al (2024) A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. Jul 30. https://doi.org/10.1007/s00415-024-12588-7. Online ahead of print. PMID: 39080054

Tanaka K, Yoshikawa M, Inoue Y et al (2024) Efgartigimod successfully ameliorated acute exacerbation of myasthenia gravis with anti-muscle-specific kinase antibodies. Intern Med. Aug 8. https://doi.org/10.2169/internalmedicine.3726-24. Online ahead of print. PMID: 3911189

Konno S, Uchi T, Kihara H, Sugimoto H (2024) Real-World case series of Efgartigimod for Japanese generalized myasthenia Gravis: Well-Tailored treatment cycle intervals contribute to sustained symptom control. Biomedicines 12(6):1214. https://doi.org/10.3390/biomedicines12061214

Article  PubMed  PubMed Central  Google Scholar 

Singer M, Khella S, Bird S et al (2024) Single institution experience with Efgartigimod in patients with myasthenia Gravis: patient selection, dosing schedules, treatment response, and adverse events. Muscle Nerve 69(1):87–92. https://doi.org/10.1002/mus.28003

Article  CAS  PubMed  Google Scholar 

Habib AA, Sacconi S, Antonini G et al Efficacy and safety of Rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia Gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III mycaring study. Ther Adv Neurol Disord 2024 Sep 12:1717562864241273036. https://doi.org/10.1177/17562864241273036